Celltrion, Inc. (KRX:068270)
South Korea · Delayed Price · Currency is KRW 174,000
+1,500 (0.87%)
Last updated: Aug 8, 2025
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2014 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2014 - 2019 |
Other | 360.00 | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | 25.00% | Log In | Log In | Log In | Log In | Upgrade |
Biopharmaceutical Medicines | 6,070.13B | Log In | Log In | Log In | Log In | Upgrade |
Biopharmaceutical Medicines Growth | 153.98% | Log In | Log In | Log In | Log In | Upgrade |
Chemical Medicines | 531.39B | Log In | Log In | Log In | Log In | Upgrade |
Chemical Medicines Growth | 3.88% | Log In | Log In | Log In | Log In | Upgrade |
Other Segments | 5.82B | Log In | Log In | Log In | Log In | Upgrade |
Other Segments Growth | 27.16% | Log In | Log In | Log In | Log In | Upgrade |
Adjustments to | -3,050.04B | Log In | Log In | Log In | Log In | Upgrade |
Adjustments to Growth | 386.58% | Log In | Log In | Log In | Log In | Upgrade |
Other | 360.00 | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | 25.00% | Log In | Log In | Log In | Log In | Upgrade |
EBIT by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2014 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2014 - 2019 |
Other | -150.00 | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | -100.00% | Log In | Log In | Log In | Log In | Upgrade |
Biopharmaceutical Medicines Operating Income | 1,199.11B | Log In | Log In | Log In | Log In | Upgrade |
Biopharmaceutical Medicines Operating Income Growth | 101.08% | Log In | Log In | Log In | Log In | Upgrade |
Chemical Medicines Operating Income | 9.18B | Log In | Log In | Log In | Log In | Upgrade |
Chemical Medicines Operating Income Growth | -74.35% | Log In | Log In | Log In | Log In | Upgrade |
Other Segments Operating Income | 505.60M | Log In | Log In | Log In | Log In | Upgrade |
Other Segments Operating Income Growth | 163.31% | Log In | Log In | Log In | Log In | Upgrade |
Adjustments to Operating Income | -716.79B | Log In | Log In | Log In | Log In | Upgrade |
Adjustments to Operating Income Growth | 503.38% | Log In | Log In | Log In | Log In | Upgrade |
Other | -150.00 | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | -100.00% | Log In | Log In | Log In | Log In | Upgrade |
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2014 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2014 - 2019 |
Domestic | 1,554.99B | Log In | Log In | Log In | Log In | Upgrade |
Domestic Growth | -15.77% | Log In | Log In | Log In | Log In | Upgrade |
Americas | - | Log In | Log In | Log In | Log In | Upgrade |
Americas Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Asia | 192.46B | Log In | Log In | Log In | Log In | Upgrade |
Asia Growth | 118.33% | Log In | Log In | Log In | Log In | Upgrade |
Europe | 1,500.81B | Log In | Log In | Log In | Log In | Upgrade |
North America | 168.09B | Log In | Log In | Log In | Log In | Upgrade |
Central and South America | 140.96B | Log In | Log In | Log In | Log In | Upgrade |